Targets › AADC
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Sep 2030.
Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine and L-5-hydroxytryptophan to serotonin. (UniProt, P20711)
Open in Phaseline: the race on AADC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Vitalgen BioPharma | VGN-R09b Gene therapy delivering AADC gene to putamen | AADC | Phase 2 | Aromatic L-amino Acid Decarboxylase Deficiency; Parkinson's Disease | Sep 2030 |
Aromatic L-amino Acid Decarboxylase Deficiency (1) Parkinson's Disease (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.